Semaglutide vs Tirzepatide
Research Verdict
Neither compound has a universal evidence advantage. Tirzepatide is the stronger research reference for weight-loss magnitude; semaglutide is the stronger research reference when mature GLP-1-only cardiovascular outcomes evidence is the priority.
Quick Answers
Which is better, Semaglutide or Tirzepatide?
Neither compound has a universal evidence advantage. Tirzepatide is the stronger research reference for weight-loss magnitude; semaglutide is the stronger research reference when mature GLP-1-only cardiovascular outcomes evidence is the priority.
What is the key difference between Semaglutide and Tirzepatide?
Tirzepatide's GIP co-agonism adds metabolic effects beyond GLP-1 alone and wins on weight-loss magnitude; semaglutide remains the GLP-1-only benchmark with broader outcomes evidence and multiple approved cardiometabolic indications.
Evidence Comparison
SURMOUNT-5 is the key update: tirzepatide produced -20.2% mean weight change at 72 weeks versus -13.7% with semaglutide 2.4mg in adults with obesity or overweight without diabetes. Semaglutide still has SELECT cardiovascular outcomes evidence in obesity (20% MACE reduction; n=17,604) and now has the higher-dose Wegovy HD 7.2mg approval.
Evidence Context Favoring Semaglutide
When GLP-1-only pharmacology, SELECT cardiovascular outcomes evidence, or Wegovy HD/formulation-specific semaglutide data is the main evidence anchor.
Evidence Context Favoring Tirzepatide
When weight-loss magnitude is the primary endpoint, or when the Zepbound obesity/OSA evidence package is the stronger fit.
Side-by-Side Snapshot
| Evidence grade | Semaglutide: Level A Tirzepatide: Level A |
|---|---|
| Research status | Semaglutide: FDA Approved Tirzepatide: FDA Approved |
| Primary category | Semaglutide: Weight Loss & Metabolic Tirzepatide: Weight Loss & Metabolic |
| Cited studies | Semaglutide: 6 Tirzepatide: 5 |